Introduction
Asthma is a chronic and allergic respiratory illness characterized by airway inflammation, remodelling and hyper-responsiveness (Busse et al. 2005) . Airway angiogenesis indicates the specific vascular structure remodelling (Ribatti et al. 2009 ). In asthma, repeated airway inflammation causes subepithelial fibrosis, airway smooth muscle (ASM) hypertrophy/hyperplasia and subepithelial basement membrane thickening, which produce airway structural changes and remodelling that involve airway angiogenesis (Detoraki et al. 2010; Yick et al. 2014) . In earlier studies, ASM cells obtained from patients with asthma were reported to be capable of promoting airway angiogenesis, although the potential mechanism is still not fully defined (Hasaneen et al. 2007; Simcock et al. 2008) .
Signal transducer and activator of transcription 3 (STAT3) is a member of the STATs family of transcription factors, which is implicated in cellular proliferation, apoptosis and migration. STAT3 could be activated by various stimuli, including cytokines and growth factor stimulation, through tyrosine phosphorylation. Accumulating evidence has proved that constitutive STAT3 activity contributes to oncogenesis in several types of cancers (Niu et al. 2002; Xu et al. 2005) . In terms of asthma, the cytokine-activated STAT3 was found to play a crucial role in lung development and asthma pathogenesis (Litonjua et al. 2005; Simeone-Penney et al. 2008) . STAT3 has been reported to be activated in the airway epithelium and is a prerequisite for allergen-induced inflammation in the murine model of chronic asthma, and blocking the STAT3 with specific inhibitors effectively reduced the airway inflammation (Simeone-Penney et al. 2007 ). STAT3 also plays crucial roles in ASM cell proliferation and asthmatic airway remodelling in humans (Wu et al. 2013) .
Vascular endothelial growth factor (VEGF) is a central pro-angiogenic growth factor necessary for normal and pathological angiogenesis that promotes the proliferation and migration of vascular endothelial cells (ECs) and smooth muscle cells (SMCs; Banerjee et al. 2008; Li et al. 2009 ). Earlier studies demonstrated that endogenous VEGF expression could be upregulated by many stimulating factors in the ASM cells from patients with chronic obstructive pulmonary disease and asthma (Faffe et al. 2005; Alagappan et al. 2007; Raidl et al. 2007) . Nevertheless, the underlying mechanism of the VEGF upregulation in the ASM cells remains to be defined.
In this study, we demonstrated that STAT3 activity in ASM was correlated with chronic asthma. Further study indicated that VEGF was the direct target of the activated STAT3, and that STAT3 induced the VEGF expression in the ASM cells. Disruption of VEGF signalling in ASM cells restrained the pro-angiogenic effect of STAT3 on the ASM cells. These data thus provide new perceptions regarding airway angiogenesis in the progression of airway remodelling and may offer a new therapeutic target for asthma.
Methods

Ethical approval
This work was done following the standards set by the Declaration of Helsinki (2008) . The study was approved by the Ethics Committee of the Cangzhou Central Hospital (24 February 2014, no. 20140013) . All the subjects gave informed consent.
Human ASM tissues
This study included glucocorticoid-free asthma patients (n = 16) and healthy control subjects (n = 6). Asthma patients and control subjects were screened for eligibility to participate according to the inclusion and exclusion criteria of the study followed by lung function measurements, including standardized spirometry and a methacholine bronchoprovocation test. Patients with mild-to-moderate asthma were diagnosed based on the Global Initiative for Asthma by the Cangzhou Central Hospital. The inclusion criteria were as follows: age, 18-50 years; and non-smoking or stopped for longer than 12 months with a smoking history of no more than 5 years. The control subjects included patients with thoracic malignancy or bronchiectasis and without any history of lung disease. Informed consents were obtained from all subjects.
The ASM tissue was obtained using the protocol and international recommendations described previously (Busse et al. 2005; Yick et al., 2013 Yick et al., , 2014 . In brief, endobronchial biopsies were obtained from the subjects. Lignocaine was sprayed in the nose and throat for local anaesthesia. To dampen the cough reflex, additional 1% lignocaine solution was then instilled into the lung during bronchoscopy. Two endobronchial biopsies per patient were collected at bronchus 4-6 branching from the stem of right lobe bronchus of the right lung with cup forceps to maximize the yield of ASM. The biopsy specimens were incubated in RNAlater, frozen overnight and cryosectioned. Laser capture microdissection was then performed to capture the ASM tissues.
Cell culture
Human ASM cells were isolated from the asthma patients and healthy control subjects according to the protocol described previously (Simcock et al. 2008) . In short, the ASM layer was isolated following the method indicated above, followed by washing, slicing and digestion in Hank's Balanced Salt Solution (HBSS) containing trypsase and collagenase for 30 min. The supernatant of the digestate was centrifuged to obtain the ASM cells. The cells were then maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), 0.5 mg l −1 epidermal growth factor, 2 mg l −1 fibroblast growth factor and 1% penicillin-streptomycin (Gibco/Invitrogen, Carlsbad, CA, USA) at 37°C in air enriched with 5% CO 2 . Cell passages 3-5 were used for the subsequent experiments (Fig. 1) . After passage, the cells were stimulated in a medium containing 10 ng ml −1 interleukin (IL)-1β, tumour necrosis factor-α (TNF-α) and interferon (IFN)-γ (Sigma, St Louis, MO, USA), to mimic the airway conditions in asthma patients, for 24 h or left untreated.
Human lung microvascular endothelial cells (HMVEC-Ls) purchased from Clonetics (San Diego, CA, USA) were maintained in M199 medium supplemented with 1% penicillin-streptomycin, 5% FBS and 0.4% human fibroblast growth factor at 37°C in air enriched with 5% CO 2 . Human aortic vascular smooth muscle cells (HAVSMCs) purchased from Invitrogen were maintained in Dulbecco's modified Eagle's medium containing 1% penicillin-streptomycin and 15% FBS.
Quantitative RT-PCR
TRIzol reagent (Sigma) was used to isolate the total RNA in the cells. The VEGF expression was detected using the CellAmp Direct RNA Prep kit for qPCR and the Protein Analysis kit (TaKaRa, Dalian, China). The primers used were as follows: VEGF, 5 -GGCTGGCAACATAACAGAGA-3 (forward) and 5 -GTGGCATGCATTGAGTCTTT-3 (reverse); and GAPDH, 5 -ACCACAGTCCATGCCATCAC-3 (forward) and 5 -ACCACAGTCCATGCCATCAC-3 (reverse). The reaction was as follows: 10 min at 95°C; 40 cycles of 1 min at 95°C; 2 min at 63°C; then 1 min at 72°C; and the final annealing step was at 72°C for 10 min. The cycle threshold (C t ) values of the GAPDH were used as the internal control. Relative expression levels were presented using the 2 − C t method. 
Western blotting
Cell lysates were prepared with lysis buffer. After centrifugation, equal amounts of the total proteins were separated using SDS-PAGE gels (Invitrogen) and electrophoretically transferred to a Poly vinylidene fluoride (PVDF) membrane. Antibodies (rabbit anti-STAT3 ab68153, phospho-STAT3 EP2147Y, 1:2000 dilution, Abcam, Cambridge, UK; mouse anti-VEGF ab69479, 1:1000 dilution, Abcam; and mouse anti-β-actin AC004, 1:3000 dilution, ABclonal, Cambridge, MA, USA) were incubated with blots overnight at 4°C, followed by incubation with secondary antibodies conjugated with horseradish peroxidase for 1 h, at room temperature. Enhanced chemiluminescence (ECL, Amersham Pharmacia, Piscataway, NY, USA) was then used to detect the bands. The intensity of the bands was measured with Image Quant software (Molecular Dynamics, Sunnyvale, CA, USA).
Cell transfection
Specific small interfering RNA (siRNA) targeting STAT3 was purchased from RiboBio (Guangzhou, China). The ASM cells grown to ß80% confluence were transfected with the STAT3 siRNA and negative control siRNA using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions. The transfection efficacy was assessed by Western blotting. After 48 h, the transfected cells were treated in the medium containing 10 ng ml −1 IL-1β, TNF-α and IFN-γ for 24 h.
Cell proliferation assay
Cell Counting Kit (CCK-8/WST-8; Bioroot, Shanghai, China) was used to measure the proliferation of the HMVEC-Ls and HAVSMCs. Briefly, conditioned medium (CM) was collected from the transfected ASM cells after 24 h of stimulation and was added into the cultured HMVEC-Ls and HAVSMCs and incubated in 96-well plates (5 × 10 4 cells ml −1 ) for 12, 24, 48 or 72 h. Next, 10 μl CCK-8 solution was added to each well for 4 h at 37°C, followed by measurement at 450 nm using the ELISA plate reader (Bio-tek, Winooski, VT, USA).
Cell migration assay
Transwell was used during the Boyden Chamber assay (6.5 mm; Costar, Cabin John, MD, USA) to test the migration of the HMVEC-Ls and HAVSMCs. Briefly, after incubation with the CM of the ASM cells for 2 days, the HMVEC-Ls and HAVSMCs were mixed in growth factor-free medium and then added into the upper gelatin-coated chamber (5 × 10 5 cells ml −1 ). Then STAT3 potentiates pro-angiogenesis in airway smooth muscle cells 600 μl medium containing 10% FBS was added into the lower compartment. Next, the cells were incubated in the chamber for 4 h, followed by fixing with 90% ethanol and staining with 0.05% Crystal Violet for 15 min. Non-transmigrated cells were gently scraped off using a cotton swab. The number of cells on the lower surface of the membrane with five fields per chamber was counted to provide quantification of cell migration.
Matrigel assay
Matrigel (Chemicon, Temecula, CA, USA) assay was used to measure the tube-formating ability of the HMVEC-Ls according to the manufacturer's manual. In brief, the HMVEC-Ls were mixed in the medium without supplements and cultured in Matrigel-coated plates. The CM of the ASM cells was added into the cultured HMVEC-Ls and incubated for 2 days. Quantification of the tubes formed by the HMVEC-Ls was measured in five fields (×20) using image analysis.
Luciferase reporter assay
The fragment containing the 5 region of the transcription initiation site of the VEGF gene was cloned into the pGL3 luciferase vector (Promega, Madison, WI, USA). Site-directed mutagenesis was introduced into the STAT3-binding site in the 5 region of the VEGF gene using QuikChange Lightning Site-Directed Mutagenesis Kits (Stratagene, La Jolla, CA, USA; pGL3-VEGF-wt: 5 -TTCCCAAA-3 ; and pGL3-VEGF-mut: 5 -CGGTCAAA-3 ). The cells were seeded (1 × 10 5 cells well −1 ) in 96-well plates and co-transfected with pGL3-VEGF, Stat3 expression vectors (donated by Yujiao Sun from Shaanxi University of Science and Technology) or in control empty vectors using Lipofectamine 2000. Reporter assays were performed with the Dual Luciferase Assay (Promega) according to the manufacturer's protocol.
Statistical analysis
All the data are presented as means ± SD. Student's paired t tests were used for comparing the significance of differences between two groups (asthma patients versus control subjects; cells treated with cytokines or not). A one-way ANOVA was used for comparing one variable among more than two treatments. Multiple comparisons of treatments were made by two-way ANOVA. A posteriori Bonferroni paired tests were carried out among treatments. A P value < 0.05 was considered statistically significant. All the statistical analysis was performed by using GraphPad Prism 6 (La Jolla, CA, USA).
Results
STAT3 is aberrantly activated in ASM cells of patients with asthma
To determine the roles of STAT3 in airway remodelling and angiogenesis, STAT3 activation in the ASM tissues of patients with asthma was examined by Western blot analysis using a phospho-STAT3 antibody. As shown in Fig. 2A, STAT3 phosphorylation was maintained at low levels in the ASM tissues of the control subjects, but was aberrantly enhanced in those tissues from the asthma patients. Furthermore, we isolated ASM cells from the biopsies of the donors and treated the isolated cells with 10 ng ml −1 IL-1β, TNF-α and IFN-γ to mimic the airway conditions in asthma patients (Simon et al. 2003; Tliba et al. 2003; Liu et al. 2015) . The activation of STAT3 was then measured in the cultured ASM cells. The results showed that the phosphorylation level of STAT3 was significantly upregulated in the ASM cells treated with cytokines compared with the untreated (NT) cells (Fig. 2B ). These data indicated that STAT3 activation in the ASM is associated with asthma.
Inhibition of STAT3 activation in ASM cells decreases the proliferation, migration and tube formation of HMVEC-Ls
We used the STAT3 inhibitor (WP1066; Gene Operation, Ann Arbor, MI, USA) and specific siRNA to elucidate the role of the STAT3 activation in airway remodelling and angiogenesis. The ASM cells were treated with the inhibitor WP1066 before being stimulated by the cytokines. As shown in Fig. 3A , the inhibitor caused downregulation of STAT3 activation in the ASM cells. Conditioned medium from the ASM cells was added into the HMVEC-Ls to monitor the capacity for pro-angiogenesis. Compared with the control conditions, inhibition of STAT3 activation in the ASM cells significantly decreased the proliferation and migration of the HMVEC-Ls (Figs 3B and 4A) . Consistently, the tube-formating ability of the HMVEC-Ls was also strongly reduced by repression of STAT3 activation in the ASM cells ( Fig. 4B and C) .
Silencing of STAT3 induced by the specific siRNA was then performed in the ASM cells. Concurring with the results obtained using the STAT3 inhibitor, endogenous STAT3 silencing in the ASM cells significantly 
Suppression of STAT3 activation in ASM cells reduces the proliferation and migration of human VSMCs
Vascular smooth muscle cells (VSMCs), another main cell type in the blood vessels, play a key role in the process of angiogenesis. We investigated the effect of STAT3 activation in the ASM cells on the motility of the VSMCs. As described earlier, the ASM cells were treated with the inhibitor WP1066 or transfected with the specific STAT3 siRNA, followed by stimulation with cytokines. Conditioned medium from the ASM cells was collected and added into the cultured VSMCs. Similar to the HMVEC-Ls, the proliferation and migration of the VSMCs were prominently restrained by the repression of STAT3 induced by the inhibitor WP1066 or siRNA in the ASM cells (Fig. 5) . These results suggested that the high activation of STAT3 in the ASM cells was significant in the regulation of promoting the angiogenesis ability of the ASM cells, which could be involved in the process of airway remodelling and angiogenesis.
STAT3 enhances the activation of VEGF signalling in cytokine-stimulated ASM cells
The VEGF signalling pathway has been proved to play a key role in the process of angiogenesis, including J. Lv and others airway angiogenesis (Ghelfi et al. 2013; Wang et al. 2015) . We investigated the potential role of VEGF signalling in the regulation of the pro-angiogenic ability of the ASM cells by STAT3 in vitro. As seen in Fig. 6A and B, both mRNA and protein levels of VEGF were upregulated in the cytokine-stimulated ASM cells. Consistently, the VEGF level in the CM of the ASM cells was also increased. However, this increase was attenuated by STAT3 silencing introduced by the specific siRNA, indicating that VEGF signalling might be involved in the STAT3-mediated pro-angiogenesis of the ASM cells.
To characterize the underlying mechanism by which VEGF signalling is modulated by STAT3 in the ASM cells, we identified the interaction between STAT3 and VEGF using luciferase reporter analysis. The wild or mutant STAT3-binding site in the 5 region of the VEGF gene was cloned into the pGL3 luciferase vector. The luciferase activities of the pGL3-VEGF-wt reporter in the ASM cells were strongly stimulated by the co-transfection of the STAT3 expression vector. However, the luciferase activities induced by STAT3 were abrogated when the mutant STAT3-binding site was introduced into the pGL3-VEGF reporter vector (Fig. 7A ). These data suggested that VEGF is a direct target of the STAT3 in the ASM cells. Furthermore, we used a VEGF neutralizing antibody (R&D Systems, Shanghai, China) to verify that STAT3-induced VEGF signalling in the ASM cells was responsible for the increased pro-angiogenic activity of the ASM cells. The VEGF neutralizing antibody was administered into the CM from the ASM cells before incubation with the HMVEC-Ls. The results revealed that the VEGF neutralizing antibody resulted in a significant reduction in the enhanced proliferation, migration and tube formation of the HMVEC-Ls induced by CM from the ASM cells stimulated with the cytokines (Fig. 7B-D) . Taken together, these results provide evidence that endogenous STAT3 mediates the pro-angiogenic ability of the ASM cells by directly activating VEGF signalling.
Discussion
The present study shows that STAT3 activity in ASM is associated with chronic asthma. VEGF was the direct target of the activated STAT3. By directly activating VEGF signalling, STAT3 mediated the pro-angiogenic ability of ASM cells. These results suggest that STAT3 activity in ASM is involved in the regulation of airway angiogenesis.
The novelty of our study is the finding of a role of STAT3 in the pro-angiogenic ability of ASM cells. Increasing evidence demonstrates that the activation of STAT3 signalling in tumours can lead to tumour angiogenesis. In tumorigenesis, STAT3 has been proved to be involved in the epidermal growth factor (EGF)-mediated prostate cancer cell progression by a cascade effect with reactive oxygen species/hypoxia-inducible factor-1α/Twist-related protein 1/N-cadherin signalling, and plays a crucial role in IL-6-induced cervical tumour growth and angiogenesis (Wei et al. 2003) . In fact, constitutive STAT3 activity contributes to oncogenesis in a wide range of cancers. Our data show that STAT3 is aberrantly activated in the ASM tissues of patients with asthma. In terms of asthma, STAT3 is reported to be activated by cytokines and plays prominent roles in ASM cell proliferation, lung development, airway inflammation and asthmatic airway remodelling in humans (Litonjua et al. 2005; Simeone-Penney et al. 2008; Wu et al. 2013) . Although the involvement of STAT3 in progression of airway diseases has been widely established, its role in asthmatic airway angiogenesis is still not well defined. In the present study, ASM cells were treated with a pro-inflammatory stimulus of IL-1β, TNF-α and IFN-γ in vitro. This stimulus was chosen to mimic closely the airway conditions in vivo, because these cytokines have been found in bronchoalveolar lavage fluid from STAT3 potentiates pro-angiogenesis in airway smooth muscle cells symptomatic patients with asthma and have been proved to induce the expression of inflammatory mediators in ASM cells (Simon et al. 2003; Tliba et al. 2003) . Herein, we determined that STAT3 activation in the ASM cells is required for the pro-angiogenic ability of the ASM cells. Both inhibition of STAT3 activity and the silencing of endogenous STAT3 in the ASM cells decreased the pro-angiogenic ability of the ASM cells to vascular ECs and SMCs in vitro.
We tried another approach to identify roles of STAT3 by elucidating the effects of STAT3 on the expression of target genes in the ASM cells. In this study, we demonstrate that VEGF is the direct target of the activated STAT3. The STAT3 regulates VEGF activation by directly interacting with the binding site in the 5 region of the VEGF gene. Conversely, disruption of the VEGF signalling in the ASM cells by specific neutralizing antibody restrains the pro-angiogenic activity of the STAT3-induced ASM cells. This observation is consistent with the results of previous studies, in which STAT3 was reported to promote tumour angiogenesis by upregulating VEGF expression (Niu et al. 2002; Wei et al. 2003; Xu et al. 2005) .
VEGF is a central pro-angiogenic factor in both normal and pathological angiogenesis and exerts a vitally important promoting effect on the proliferation and migration of ECs and SMCs by binding with the specific receptor VEGFR and activating multiple signalling pathways (Banerjee et al. 2008; Li et al. 2009 ). In asthma, increased VEGF levels are detected in the ASM cells, which are correlated with the degree of mucosal vascularity (Ghelfi et al. 2013) . Endogenous VEGF expression can be induced by various stimulatory factors in ASM cells from patients with asthma and chronic obstructive pulmonary disease. In fact, the TNF-α induces VEGF expression in the ASM cells from smokers with chronic obstructive pulmonary disease by reducing the acetylation status of the VEGF promoter (Raidl et al. 2007) . Oncostatin M increases VEGF expression and release in human ASM cells by synergizing with IL-1β (Faffe et al. 2005) . The expression and secretion of VEGF can also be induced by the vasoactive peptides angiotensin II and endothelin-1 in human ASM cells (Alagappan et al. 2007) . The involvement of VEGF in the STAT3-mediated pro-angiogenic activity of the ASM cells suggests that the activated ASM cells could play a promoting role in airway angiogenesis during pathological airway remodelling in asthma, and this regulatory activity of the ASM cells is correlated with the STAT3/VEGF signalling cascade.
To summarize, we demonstrate the crucial role of STAT3 activation in ASM cells in the ASM-induced regulation of airway angiogenesis in vitro. The STAT3 activity in the ASM cells is correlated with chronic asthma by direct activation of VEGF signalling. This may represent a possible therapeutic target for asthma.
